
Esophageal Cancer Photodynamic Therapy: Japan's Salvage Option
Photodynamic therapy for esophageal cancer remaining after radiotherapy: approved in Japan in 2015, with local complete response in 88.5% in phase II.
Read more
Articles on Photoimmunotherapy: up-to-date treatment information based on published sources and papers, with references.
Illustrative image

Photodynamic therapy for esophageal cancer remaining after radiotherapy: approved in Japan in 2015, with local complete response in 88.5% in phase II.
Read more
Photoimmunotherapy step by step: infusion, laser 20–28 hours later, light protection, about two weeks in hospital and repeat cycles, with Japanese results.
Read more
ESMO 2026 long-term data on photoimmunotherapy (ASP-1929) plus pembrolizumab in head and neck cancer: 5 of 17 complete responses, median OS 28.2 months.
Read more
PDT vs photoimmunotherapy compared: 88.5% complete response with PDT for esophageal cancer in Japan, 75.0% response with head and neck photoimmunotherapy, and light avoidance.
Read more
The FDA approved Ameluz red-light photodynamic therapy for superficial basal cell carcinoma in September 2026. Phase 3 results, procedure and side effects.
Read more
Head and neck cancer photoimmunotherapy, approved in Japan in 2020: 43.3% responded in a phase 1/2a trial and 75.0% in a 40-patient Japanese study.
Read more
Glioblastoma photodynamic therapy with talaporfin is insurance-covered in Japan since 2013. Phase 2: 100% 1-year survival, plus recurrent-tumour results.
Read more
Gan Chuo Clinic’s “cancer photoimmunotherapy” and the head and neck cancer treatment approved in Japan use different drugs. Here is how to tell them apart.
Read moreNo results found.